Engine Alliance Selects CTS Engines to Provide MRO Engine Services for the GP7200
24.5.2023 15:00:00 EEST | Business Wire | Press release
CTS Engines (CTS) announces they have been selected to provide MRO services for Engine Alliance (EA) on the GP7200 turbofan jet engine. EA is a 50-50 joint venture between Pratt & Whitney and General Electric for the development, production, and service of the GP7200. The GP7200 is the premier engine for the A380 aircraft as it combines the reliability and ingenuity of the PW4000 and GE90 engines while providing the most fuel-efficient and quietest powerplant for the A380.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230524005295/en/
Engine Alliance selects CTS Engines to provide MRO Engine Services for the GP7200 (Graphic: Business Wire)
“In 2019, Engine Alliance changed its operational focus to aftermarket services and customer support. The partnership with CTS will help us meet our customers’ high expectations,” said Amy Johnston, President of EA. “CTS leadership team provides a unique perspective that comes from years of experience at airlines, MRO shops, and the OEMs, and we are confident CTS will deliver the results our airline customers require,” stated Johnston.
“We are excited to partner with EA to provide MRO services for the GP7200. This is a fantastic opportunity for us to learn the best practices from the world’s greatest engine companies while also delivering world-class quality, reliability, and turnaround time,” said Vesa Paukkeri, Chief Executive Officer of CTS.
About CTS Engines
CTS Engines is a global leader in mature engine maintenance, rethinking business as usual. Based in Fort Lauderdale, FL, CTS Engines is an independent MRO providing complete maintenance, repair, overhaul, and testing services to owners and operators of mature wide-body aircraft engines. We proudly support a wide range of both commercial and military customers. Since 2002, CTS Engines has built its reputation on the ability to provide its customers with high-quality, cost-effective solutions for engine maintenance. Our mission is to keep our customers’ mature engines flying longer and more reliably than any other MRO in the world.
About Engine Alliance
Engine Alliance (EA) is a 50-50 joint venture of GE (NYSE:GE) and Pratt & Whitney (P&W), a Raytheon Technologies business (NYSE:RTX). Revenue-sharing partners include MTU Aero Engines of Germany, SAFRAN Aero Boosters of Belgium and SAFRAN Aircraft Engines of France. EA manufactures and services the quietest, most reliable and most fuel-efficient powerplant for the A380, the GP7200.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005295/en/
Contact information
For more information, press only:
CTS Engines
Alejandra Meza
AMeza@ctsengines.com
For more information on CTS Engines please visit our website:
www.CTSEngines.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release
QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems
Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership15.9.2026 12:16:00 EEST | Press release
Axo Longevity today announced the close of an oversubscribed $5M seed round to expand its preventive health membership across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910642125/en/ Axo Longevity preventive health membership The round was backed by MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital and NIAN Sports & Entertainment, alongside angel investors including Dr. Jorge Planas of Clinica Planas Barcelona and Daniel Kulle, former President of H&M and former CEO of Forever 21. Developed to help people understand what is happening inside their body before symptoms appear, Axo Longevity moved from build to live operations in just twelve weeks. The platform is expanding globally, now operating in the United Kingdom, Ireland, Spain, Germany, and the Netherlands, as well as in its first Latin American market, Peru. It is supported by more than 1,400 laboratory
Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth15.9.2026 12:00:00 EEST | Press release
Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026. David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development. Following a thorough selection process led by the Board of Directors, David will succeed Interim Group CEO Jean-Marc Bellemin, who has successfully led the Group since 15 May 2026, while also continuing in his permanent role as Group CFO. Maria Paola Chiesi, Chiesi Group Chair, commented: “We are delighted to welcome David to Chiesi at a time of strong momentum for the company. Innovati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom